12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

HA-Irinotecan: Phase III ongoing

Alchemia said an independent DSMB for a second time recommended continuation of the double-blind, international Phase III ACO002 trial of HA-Irinotecan after a review of data from 220 patients found no safety...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >